Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals

Molecular and Cellular Biochemistry

Volumn 269, Issue 1, 2005, Pages 143-152

  Panov, Alexander V ^a   Lund, Serena ^a   Greenamyre, J Timothy ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Huntington's Dis Society of America   (United States)

Author keywords

Calcium retention capacity; Human lymphoblast cells; Huntington's disease; Membrane potential; Mitochondria; Mitochondrial respiration; Permeability transition

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; CYCLOSPORIN A; GLUTAMIC ACID; HUNTINGTIN; MALIC ACID; OLIGOMYCIN; SUCCINIC ACID; CALCIUM; CYCLOSPORIN; DIVALENT CATION; ENZYME INHIBITOR; HD PROTEIN, HUMAN; HDH PROTEIN, RAT; NERVE PROTEIN; NUCLEAR PROTEIN;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; BLOOD CELL; CALCIUM TRANSPORT; CASE REPORT; CELL LINE; CELL SWELLING; CONTROLLED STUDY; DIAPHRAGM PARALYSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; ISOLATION PROCEDURE; LEUKOCYTE CULTURE; LYMPHOBLASTOID CELL; MEMBRANE CONDUCTANCE; MEMBRANE DEPOLARIZATION; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; METABOLISM; MITOCHONDRIAL MEMBRANE; NONHUMAN; ONSET AGE; OXIDATIVE PHOSPHORYLATION; PROTON TRANSPORT; QUALITATIVE ANALYSIS; RAT; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; LEUKOCYTE; MITOCHONDRION; MITOCHONDRION SWELLING; PERMEABILITY; PHYSIOLOGY;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ANIMALS; CALCIUM; CATIONS, DIVALENT; CYCLOSPORINE; ENZYME INHIBITORS; HUMANS; HUNTINGTON DISEASE; LEUKOCYTES; MITOCHONDRIA; MITOCHONDRIAL SWELLING; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGOMYCINS; PERMEABILITY; RATS;

EID: 14244264746     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-3454-9     Document Type: Article

References (51)

1. Petersen A, Mani K, Brundin P: Recent advances on the pathogenesis of Huntington's disease. Experim Neurology 157: 1-18, 1999
2. Rigamonti D, Nauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E: Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20: 3705-3713, 2000
3. Liu YF: Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 273: 28873-28877, 1998
4. Lear JD: Polyglutamine toxicity: A new idea for a tough problem. Biophys J 78: 2733-2734, 2000
5. Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66, 1998 10.1016/ S0092-8674(00)81782-1
6. Cummings CJ, Zoghbi HY: Trinucleotide repeats: Mechanisms and pathophysiology. Ann Rev Hum Genet 1: 281-328, 2000
7. Schapira AH: Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1410: 159-170, 1999
8. Vonsattel JP, DiFiglia M: Huntington's disease. J Neuropathol Exp Neurol 57: 369-384, 1998 1:STN:280:DyaK1c3lsFyntQ%3D%3D
9. Strong TV, Tagle DA, Valdes JM: Widespread expression of the human and rat Huntington's disease gene in brain and non-neural tissues. Nat Genet 5: 259-265, 1993
10. Nicholls DG, Budd SL: Mitochondria and neuronal survival. Physiol Rev 80: 315-360, 2000
11. Bernardi P: Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev 79: 1127-1155, 1999
12. Crompton M: The mitochondrial permeability transition pore and its role in cell death. Biochem J 341: 233-249, 1999
13. Petit PX, Susin S-A, Zamzami N, Mignotte B, Kroemer G: Mitochondria and programmed cell death: Back to the future. FEBS Letters 396: 7-13, 1996
14. 2+ -dependent permeability transition and Complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease. Ann NY Acad Sci 893: 365-368, 1999
15. Beutner G, Ruck A, Riede B, Brdiczka D: Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1368: 7-18, 1998
16. Shimizu S, Narita M, Tsujimoto Y: Bcl-2 family proteins regulate therelease of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487, 1999 10.1038/20959
17. Panov A, Andreeva L, Greenamyre JT: Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: Comparison of rat liver and brain mitochondria. Arch Biochem Biophys, in press
18. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC: The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427: 461-465, 2004 10.1038/nature02229
19. Kushnareva YuE, Campo ML, Kinnally KW, Sokolove PM: Signal presequences increase mitochondrial permeability and open multiple conductance channel. Arch Biochem Biophys 366: 107-115, 1999
20. Trounce IA, Kim YL, Jun AS, Wallace DC: Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264: 484-509, 1996
21. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF, Jr, Greenamyre JT, Snyder SH, Ross CA: Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nature Medicine 5: 1194-1198, 1999
22. Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT: Early mitochondrial calcium defects in Huntington's Disease area direct effect of polyglutamines. Nature Neurosci 5: 731-736, 2002
23. Wallace DC: Mitochondrial diseases in man and mouse. Science 283: 1482-1488, 1999 10.1126/science.283.5407.1482
24. Brustovetsky N, Brustovetsky T, Jemmerson R, Dubinsky JM: Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J Neurochem 80: 207-218, 2000
25. Shabalina IG, Panov AV: Control of energization of the liver mitochondria at the level of the adenine nucleotides carrier under condition of low tonicityof the incubation medium. Biochemistry (Moscow) 56: 282-287, 1991
26. + ions. Arch Biochem Biophys 199: 420-426, 1980
27. 2+ control of respiration in isolated rat liver mitochondria. Biochemistry 35: 12849-12856, 1996
28. LaNoue KF, Strzelecki T, Strzelecka D, Koch C: Regulation of the uncoupling protein in brown adipose tissue. J Biol Chem 261: 298-305, 1986
29. AP Halestrap JD McGivan 1989 Measurement of membrane transport phenomena H.L. Kornberg J.C. Metcalfe D.H. Northcote C.I. Pogson K.F. Tipton (eds) Techniques in Meta bolic Research Elsevier North-Holland, Amsterdam 1 23 Vol. B206
30. Tsien RY, Rink TJ: Neutral carrier ion-selective microelectrodes for measurement of intracellular free calcium. Biochim Biophys Acta 599: 623-638, 1980
31. Chalmers S, Nicholls DG: The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem 278: 19062-19070, 2003
32. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman J-W, Cooper JM, Schapira AHV: Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45: 25-32, 1999 10.1002/ 1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E
33. Tatton WG, Olanow CW: Apoptosis in neurodegenerative diseases: The role of mitochondria. Biochim Biophys Acta 1410: 195-213, 1999
34. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF: Energy metabolism defects in Huntington's disease and effects of coenzyme Q. Ann Neurol 41: 160-165, 1997
35. Cortopassi GA, Wong A: Mitochondria in organismal aging and degeneration. Biochim Biophys Acta 1410: 183-193, 1999
36. Rego AC, Oliveira CR: Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: Implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 28: 1563-1574, 2003
37. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM: Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Mol Genet 9: 1259-1271, 2000
38. Krohn, AJ, Wahlbrink T, Prehn JHM: Mitochondrial depolarization is not required for neuronal apoptosis. J Neurosci 19: 7394-7404, 1999
39. Savage MK, Reed DJ: Release of mitochondrial glutathione and calciumby a cyclosporin A-sensitive mechanism occurs without large amplitude swelling. Arch Biochem Biophys 315: 142-152, 1994
40. Mannella CA, Pfeiffer DR, Bradshaw PC, Moraru II, Slepchenko B, LoewLM, Hsieh C-E, Buttle K, Marko M: Topology of the mitochondrial inner membrane: Dynamics and bioenergetic implications. IUBMB Life 52: 93-100, 2001
41. 2+-dependent depolarization of rat liver and human lymphoblast mitochondria: Relevance to Huntington's disease. Arch Biochem Biophys 410: 1-6, 2003
42. Kushnareva YE, Sokolove PM: Prooxidants open both the mitochondrial permeability transition pore and a low-conductance channel in the inner mitochondrial membrane. Arch Biochem Biophys 376: 377-388, 2000
43. DG Nicholls SJ Ferguson 2002 Bioenergetics 3 Academic Press London
44. Monoi H, Futaki S, Kugimiya S-C, Minakata H, Yoshihara K: Poly-l-glutamine forms cation channels: Relevance to the pathogenesis of the polyglutamine diseases. Biophys J 78: 2892-2899, 2000
45. Norremolle A, Grunnet M, Hasholt L, Sorensen SA: Cells exposed to a huntingtin fragment containing an expanded polyglutamine tract show no sign of ion channel formation: Results arguing against the ion channel hypothesis. J Neurosci Res 71: 132-137, 2003
46. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR: Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J Biol Chem 275: 19831-19838, 2000
47. Hansson MJ, Persson T, Friberg H, Keep MF, Rees A, Wieloch T, Elmer E: Powerful cyclosporin inhibition of calcium-induced permeability transition in brain mitochondria. Brain Res 960: 99-110, 2002
48. Schapira AHV: Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment. Ann Neurol 41: 141-142, 1997
49. Nishino H, Hida H, Kumazaki M, Shimano Y, Nakajima K, Shimizu H, Ooiwa T, Baba H: The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: A hypothesis to explain its specific vulnerability. J Neurotrauma 17(3): 251-260, 2000
50. Greene JG, Greenamyre JT: Bioenergetics and glutamate excitotoxicity. Progr Neurobiol 48: 613-634, 1996
51. Alexia T, Borlongand CV, Faullb RLM, Williamsa CE, Clarka RG, Gluckmana PD, Hughesc PE: Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Progr Neurobiol 60: 409-470, 2000